Radotinib as 3rd or Later Line Therapy in CP-CML

Inclusion Criteria: * Chronic myeloid leukemia chronic phase (CP-CML) patients who are not tolerable or resistant to prior 2 or more tyrosine kinase inhibitors (TKIs). * ECOG 0, 1, 2 * Patients who are agree and signed to informed consent. Exclusion Criteria: * T315I mutation * Prior exposure to radotinib * Accelerated or blastic phase * galactose intolerance, severe lactase deficiency or glucose galactose malabsorption * Prior history of intensive cytotoxic chemotherapy except for TKIs * Significant cardiac problem * QTcF \> 450 msec * Pancreatitis history prior to study enrollment * Clinically significant malignant disease other than CML * Pregnant or breast feeding woman